CBDV and CBD Composition for Epilepsy Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy are often ineffective for 30% of patients and come with notable motor side effects, highlighting the need for alternative drugs that can safely and effectively manage hyper-excitability of the central nervous system and seizures.
Innovation Solution
A pharmaceutical composition comprising cannabidivarin (CBDV) and cannabidiol (CBD), preferably with terpene fractions, and absent or substantially absent of THC and THCV, is developed to treat neurological conditions like epilepsy, providing a safer and more effective option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-epileptic drugs are used, then seizure control is achieved in some patients, but motor side effects occur and 30% of patients remain ineffective
Solution Approach 1:
The patent extracts and isolates specific anti-convulsant compounds (CBDV and CBD) from the cannabis plant, separating them from other cannabinoids like THC and THCV that may cause harmful side effects. This extraction allows for targeted therapeutic action while eliminating unwanted psychoactive and pro-convulsant effects, directly resolving the contradiction between effectiveness and side effects
Solution Approach 2:
The patent changes the chemical composition parameters by defining specific ratios of CBDV to CBD (from 1:1 to 10:1) and controlling the absence of THC and THCV. This parameter optimization ensures maximum anti-convulsant efficacy while minimizing side effects, addressing both the effectiveness and safety concerns of conventional treatments
2Reliability
If cannabis chemotypes containing significant amounts of CBDV and/or CBD are used, then anti-convulsant effects are achieved, but THC and THCV are also present which may have pro-convulsant effects
Solution Approach 1:
The patent applies extraction by removing harmful cannabinoids (THC and THCV) from the cannabis-derived composition while retaining the beneficial CBDV and CBD. This selective removal eliminates the pro-convulsant effects while preserving the anti-convulsant properties, directly resolving the contradiction between therapeutic benefit and harmful byproducts
Solution Approach 2:
The patent creates a composite pharmaceutical composition with a specific formulation of CBDV, CBD, and optional terpenes, while excluding harmful cannabinoids. This controlled composite material combines synergistic components (CBDV and CBD work together) while avoiding antagonistic components (THC and THCV), achieving net anti-convulsant effect without pro-convulsant risks
Data Source
AI summary
This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.